Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 5/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 5/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.39 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL823719 | 0.88 | MAP4K4 (0.52) | MKNK1MKNK2ALDH1A1TLR7MAP4K4 | |
| SCHEMBL823810 | 0.88 | NAMPT (0.42) | MKNK1MKNK2NPC1RAB9AKDM4E | |
| SCHEMBL825764 | 0.88 | MKNK1 (0.41) | MKNK1MKNK2NPC1RAB9AKDM4E | |
| SCHEMBL826099 | 0.87 | MKNK1 (0.40) | MKNK1MKNK2NPC1RAB9AKDM4E | |
| SCHEMBL823648 | 0.86 | HPGD (0.50) | MKNK1MKNK2KDM4EHPGDNAMPT | |
| SCHEMBL823761 | 0.85 | MKNK2 (0.38) | MKNK1MKNK2NPC1RAB9AALDH1A1 | |
| SCHEMBL823762 | 0.85 | MKNK2 (0.47) | MKNK1MKNK2BACE1MAP4K4 | |
| SCHEMBL823718 | 0.84 | MAP4K4 (0.41) | MKNK1MKNK2MAP4K4 | |
| SCHEMBL4425330 | 0.83 | CHEK2 (0.45) | MKNK1MKNK2TLR8MAP4K4 | |
| SCHEMBL3331769 | 0.83 | KDM4E (0.47) | NPC1RAB9AKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090324543-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC (US) | 2009-12-31 | — | — | US | claimed |
| US-8143394-B2 | Pyrido(3,2-d)pyrimidines useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143394-B2 | Pyrido(3,2-d)pyrimidines useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143394-B2 | Pyrido(3,2-d)pyrimidines useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20090324543-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090324543-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090324543-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC (US) | 2009-12-31 | — | — | US | disclosed |
| WO-2008077649-A1 | PYRIDO(3,2-D)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTONS | GILEAD SCIENCES, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090324543-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | PNPO, DPYD, PLPBP | MKNK1 3271/4885MKNK2 3173/4885NPC1 3135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.